Open original FDA record ↗Recall record
- FDA identifier
- Z-1097-2007
- Company in FDA record
- Abbott Diagnostic International, Ltd.
- FDA classification date
- Jul 24, 2007
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 20, 2026
- Recall classification
- Unknown — no matched enforcement classification
Reason stated in the source
During an internal study, the Architect AUSAB assay was found to read preparations of the WHO standard up to 53% higher than the WHO assigned value. This has the potential to cause elevated results and may impact the interpretation for a small percentage of results with grayzone or low-level reactive concentrations and higher proficiency sample results.
Source facts
- Action
- All ARCHITECT AUSAB U.S. customers will be contacted. New customers will be contacted through a Product Information Letter that will be included in all ARCHITECT AUSAB Reagent Kits until assay is restandardized. All ARCHITECT AUSAB U.S. customers will be contacted. The following communication types were used: Product Correction Letter Customer Reply Form > Product Information Letter to be included in new kits to be distributed. Letters were sent to customers by Federal Express Priority mail. The Customers were instructed to: Please follow their laboratory procedures for evaluation of these results Disregard the automated interpretation of results for low-level reactive samples. A customer reply form will accompany the Product Correction letter. Effectiveness Check Depth: 100% of customers receiving the Product Correction letter. The start date of communication was May 14,2007.
- Initiated
- 2007-05-14
- Root cause
- Other
- Terminated
- 2011-06-10
- Distribution
- Nationwide and Puerto Rico
- Recall number
- Z-1097-2007
- Recall status
- Terminated
- CDRH record ID
- 52497
- FDA classified
- 2007-07-24
- Recall event number
- 37961